Research Peptides
A high-purity research peptide studied in growth-hormone research. Available in 5mg and 10mg, with every batch independently tested and dispatched from the UK.
A high-purity research peptide studied in growth-hormone research. Available in 5mg and 10mg, with every batch independently tested and dispatched from the UK.
Sermorelin peptide UK is Crown Peptides' synthetic analogue of growth-hormone-releasing hormone 1-29, supplied in 5mg and 10mg vials for laboratory research into GHRH receptor pharmacology and pituitary signalling.
Supplied for laboratory research purposes only — not for human consumption or for medical, veterinary or diagnostic use.
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth-hormone-releasing hormone, the region responsible for receptor activity. It is therefore used in endocrine research as a defined GHRH-receptor agonist.
Sermorelin research examines GHRH receptor pharmacology, pituitary somatotroph signalling, growth-hormone release and downstream endocrine feedback, with structure-activity studies mapping the receptor-active region of the GHRH(1-29) sequence in detail (Learn more). Its relatively short sequence allows researchers to study the active N-terminal region of GHRH without using the full endogenous peptide, alongside related growth-hormone-secretagogue peptides such as [CJC-1295 with DAC] and [Ipamorelin].
Compound-level reference data. Batch-specific results appear on the Certificate of Analysis.
Work out concentration with the peptide calculatorCrown Peptides Sermorelin is supplied for controlled laboratory research with batch-specific analytical documentation. High-Performance Liquid Chromatography (HPLC) can assess chromatographic purity, while Mass Spectrometry provides molecular information used to support identity verification. The batch-specific Certificate of Analysis is the definitive source for the exact purity result, identity data and analytical specification of the material supplied.
Researchers working with Sermorelin may also be interested in [CJC-1295 with DAC], [CJC-1295 + Ipamorelin], [Ipamorelin], [GHRP-6] and [Tesamorelin] — other growth-hormone-secretagogue peptides studied in related research areas.
Sermorelin is a synthetic 29-amino-acid analogue corresponding to the active N-terminal region of human GHRH, supplied by Crown Peptides in 5mg and 10mg vials.
It is studied through the growth-hormone-releasing hormone receptor.
Research includes pituitary signalling, growth-hormone release, GHRH receptor pharmacology and endocrine feedback.
The first 29 amino acids of GHRH contain the receptor-active region, allowing this shorter sequence to be studied independently.
HPLC and Mass Spectrometry can assess peptide purity and identity, with exact batch results recorded on the Certificate of Analysis.
Every batch is published openly — identity, purity and batch number, with no account needed.
Supplied for laboratory research purposes only — not for human consumption or for medical, veterinary or diagnostic use.
Each batch undergoes internal analytical verification using chromatographic and spectrometric methods prior to lyophilisation.
• HPLC Analysis
• Mass Spectrometry Confirmation
• Batch Traceability
By purchasing this product you confirm that you are a qualified researcher and that this compound will be used exclusively for laboratory research purposes.
This product is not intended for diagnostic or therapeutic use.
Any human or medical use is strictly prohibited.
Store in a cool, dry, secure and sterile environment away from any unauthorised persons or children.
Disclaimer: All products are sold strictly for laboratory research purposes only. Not for human or veterinary use, consumption, therapeutic, or diagnostic application. By purchasing, you confirm you are a qualified professional and legally permitted to handle these materials in compliance with all applicable laws and regulations. Misuse, resale for unauthorised purposes, or unlawful application is strictly prohibited. Crown Peptides UK disclaims all liability for improper use, handling, or regulatory non-compliance.